Open access
Oct 2026
Clinical utility of circulating tumor cell PD-L1 expression for predicting immunotherapeutic response and prognosis in esophageal cancer
Background Immune checkpoint inhibitors (ICIs) have improved outcomes in esophageal cancer, yet reliable biomarkers remain lacking. Tissue PD-L1 testing is limited by intratumoral heterogeneity and invasiveness, whereas circulating tumor cells (CTCs) offer a non-invasive alternative. This study evaluated CTC PD-L1 expr...
Jing Li, Yue-Ze Li, Lin Chen et al.
· The journal of liquid biopsy · 0 citations